Michael R.  Minogue net worth and biography

Michael Minogue Biography and Net Worth

CEO of Abiomed
Chairman, President and Chief Executive Officer, ABIOMED, Inc. Mr. Michael R. Minogue has been Chairman, President and Chief Executive Officer of ABIOMED, Inc. since 2004. Mr. Minogue transitioned the Company’s mission to creating the field of heart recovery with the acquisition and development of new technologies such as the Impella®, the world’s smallest heart pump, and extracorporeal membrane oxygenation (ECMO). ABIOMED has been one of the fastest growing, GAAP profitable medtech companies and ranked the third best performing stock on the S&P 500 for the last decade. ABIOMED has earned numerous global regulatory approvals on new products and indications in the United States, Europe, Japan and other countries. ABIOMED employs approximately 1,500 people with facilities in Danvers, Massachusetts, Aachen and Berlin, Germany and Tokyo, Japan. In addition to his responsibilities at ABIOMED, Mr. Minogue currently serves on the medical device industry association board of directors for AdvaMed, and serves on the board for the Medical Device Innovation Consortium (MDIC). He also serves on Insulet Corporation’s Board of Directors and was on the boards of LifeCell and Bioventus. Before joining ABIOMED, Mr. Minogue spent 11 years with General Electric Healthcare, where he held numerous leadership positions and holds three patents. Mr. Minogue also served as an officer in the U.S. Army, which included multiple distinctions including Airborne, Ranger, Desert Storm Veteran and Bronze Star. He received his Bachelor of Science degree in Engineering Management from the United States Military Academy at West Point and his Master of Business Administration from the University of Chicago. Mr. Minogue co-founded the Mike and Renee Minogue Foundation and the Mentoring Veterans Program (MVPvets) (www.mvpvets.org), a 501(c)(3) nonprofit organization that helps military veterans network with industry mentors to discover career opportunities in the medtech industy. He serves on the Board of Directors after serving as the Chairman for the past eight years. Mr. Minogue is the Chairman of the Governor’s Advisory Council on Veterans’ Services for Massachusetts and supports the Inner-City Scholarship Fund, Boys and Girls Club, and multiple educational initiatives. Mr. Minogue is married with five children and enjoys reading, mentoring, running, coaching, skiing and playing sports. Provided by Tagnifi.

What is Michael R. Minogue's net worth?

The estimated net worth of Michael R. Minogue is at least $90.16 million as of June 21st, 2021. Mr. Minogue owns 236,635 shares of Abiomed stock worth more than $90,162,668 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. Minogue may own. Additionally, Mr. Minogue receives a salary of $3,040,000.00 as CEO at Abiomed. Learn More about Michael R. Minogue's net worth.

How old is Michael R. Minogue?

Mr. Minogue is currently 56 years old. There are 5 older executives and no younger executives at Abiomed. Learn More on Michael R. Minogue's age.

What is Michael R. Minogue's salary?

As the CEO of Abiomed, Inc., Mr. Minogue earns $3,040,000.00 per year. Learn More on Michael R. Minogue's salary.

How do I contact Michael R. Minogue?

The corporate mailing address for Mr. Minogue and other Abiomed executives is 22 CHERRY HILL DR, DANVERS MA, 01923. Abiomed can also be reached via phone at (978) 646-1400 and via email at [email protected]. Learn More on Michael R. Minogue's contact information.

Has Michael R. Minogue been buying or selling shares of Abiomed?

Michael R. Minogue has not been actively trading shares of Abiomed during the last quarter. Most recently, Michael R. Minogue sold 3,492 shares of the business's stock in a transaction on Monday, August 23rd. The shares were sold at an average price of $350.00, for a transaction totalling $1,222,200.00. Learn More on Michael R. Minogue's trading history.

Who are Abiomed's active insiders?

Abiomed's insider roster includes Marc Began (VP), Andrew Greenfield (VP), Michael Minogue (CEO), Michael Minogue (CEO), Dorothy Puhy (Director), Joseph Riccelli, Sr. (CEO), Martin Sutter (Director), Paul Thomas (Director), Todd Trapp (CFO), David Weber (COO), and Magdalena Yesil (Director). Learn More on Abiomed's active insiders.

Michael R. Minogue Insider Trading History at Abiomed

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2021Sell3,492$350.00$1,222,200.00View SEC Filing Icon  
8/9/2021Sell7,037$350.00$2,462,950.00236,106View SEC Filing Icon  
8/6/2021Sell24,471$350.00$8,564,850.00236,106View SEC Filing Icon  
6/21/2021Sell25,000$325.35$8,133,750.00236,635View SEC Filing Icon  
8/21/2020Sell100,000$309.12$30,912,000.00
6/21/2018Sell105,000$439.69$46,167,450.00481,150View SEC Filing Icon  
9/22/2016Sell28,039$127.07$3,562,915.73215,488View SEC Filing Icon  
9/21/2016Sell5,034$127.07$639,670.38215,782View SEC Filing Icon  
9/19/2016Sell58,710$127.00$7,456,170.00215,782View SEC Filing Icon  
8/19/2015Sell146,800$104.87$15,394,916.00239,718View SEC Filing Icon  
5/6/2015Sell8,840$73.12$646,380.80View SEC Filing Icon  
10/31/2014Sell164,000$31.14$5,106,960.00View SEC Filing Icon  
7/28/2014Sell82,383$26.30$2,166,672.90View SEC Filing Icon  
5/27/2014Sell90,001$21.19$1,907,121.19View SEC Filing Icon  
7/31/2013Sell36,500$25.04$913,960.00View SEC Filing Icon  
6/4/2013Sell17,667$21.23$375,070.41View SEC Filing Icon  
5/29/2013Sell58,833$21.83$1,284,324.39View SEC Filing Icon  
5/23/2013Sell5,666$21.62$122,498.92View SEC Filing Icon  
5/9/2013Sell20,000$21.00$420,000.00View SEC Filing Icon  
See Full Table

Michael R. Minogue Buying and Selling Activity at Abiomed

This chart shows Michael R Minogue's buying and selling at Abiomed by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Abiomed Company Overview

Abiomed logo
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
Read More

Today's Range

Now: $381.02
Low: $381.02
High: $381.02

50 Day Range

MA: $380.55
Low: $377.20
High: $381.30

2 Week Range

Now: $381.02
Low: $219.85
High: $381.99

Volume

258 shs

Average Volume

611,028 shs

Market Capitalization

$17.18 billion

P/E Ratio

65.47

Dividend Yield

N/A

Beta

1.4